ReviewMolecular aspects of medicine2013
Obesity pharmacotherapy: what is next?
Review in Molecular aspects of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Circulating acyl and des-acyl ghrelin levels in obese adults: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Influence of the Tissue Collection Procedure on the Adipogenic Differentiation of Human Stem Cells: Ischemic versus Well-Vascularized Adipose Tissue.Biomedicines · 2024Article
- Detection of natural autoimmunity to ghrelin in diabetes mellitus.Frontiers in medical technology · 2024Article
- Pharmacophore-based virtual screening from phytocannabinoids as antagonist r-CB1.Journal of molecular modeling · 2022Article
- The genus Rumex (Polygonaceae): an ethnobotanical, phytochemical and pharmacological review.Natural products and bioprospecting · 2022Review
- Histamine HPharmaceuticals (Basel, Switzerland) · 2021Article
- Targeting Energy Expenditure-Drugs for Obesity Treatment.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects.Future medicinal chemistry · 2020Review
- Insights on Obesity in Children and Adults: Individualizing Management.Trends in endocrinology and metabolism: TEM · 2019Review
- Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.Current obesity reports · 2018Review
- Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Fungal endophytes associated with Viola odorata Linn. as bioresource for pancreatic lipase inhibitors.BMC complementary and alternative medicine · 2017Article
- Obesity: Current and potential pharmacotherapeutics and targets.Pharmacology & therapeutics · 2017Review
- Myricetin protects against diet-induced obesity and ameliorates oxidative stress in C57BL/6 mice.Journal of Zhejiang University. Science. B · 2016Article
- Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence?International journal of obesity (2005) · 2016Review
- Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2015Review
- Anti-ghrelin antibodies in appetite suppression: recent advances in obesity pharmacotherapy.ImmunoTargets and therapy · 2015Review
- Fenugreek seed extract inhibit fat accumulation and ameliorates dyslipidemia in high fat diet-induced obese rats.BioMed research international · 2014Article
- Brain delivery of proteins via their fatty acid and block copolymer modifications.Journal of drug targeting · 2013Review
- Effects of a leucine and pyridoxine-containing nutraceutical on body weight and composition in obese subjects.Diabetes, metabolic syndrome and obesity : targets and therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The increase in obesity in the Unites States and around the world in the last decade is overwhelming. The number of overweight adults in the world surpassed 1 billion in 2008. Health hazards associated with obesity are serious and include heart disease, sleep apnea, diabetes, and cancer. Although lifestyle modifications are the most straightforward way to control weight, a large portion of the population may not be able to rely on this modality alone. Thus, the development of anti-obesity therapeutics represents a major unmet medical need. Historically, anti-obesity pharmacotherapies have been unsafe and minimally efficacious. A better understanding of the biology of appetite and metabolism provides an opportunity to develop drugs that may offer safer and more effective alternatives for weight management. This review discusses drugs that are currently on the market and in development as anti-obesity therapeutics based on their target and mechanism of action. It should serve as a roadmap to establish expectations for the near future for anti-obesity drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.